Attached files
| file | filename |
|---|---|
| 10-K - ANTARES PHARMA, INC. | k10.htm |
| EX-21.1 - ANTARES PHARMA, INC. | ex211.htm |
| EX-32.1 - ANTARES PHARMA, INC. | ex321.htm |
| EX-31.2 - ANTARES PHARMA, INC. | ex312.htm |
| EX-31.1 - ANTARES PHARMA, INC. | ex311.htm |
| EX-32.2 - ANTARES PHARMA, INC. | ex322.htm |
Exhibit 23.1
Consent
of Independent Registered Public Accounting Firm
The Board
of Directors and Shareholders
Antares
Pharma, Inc.:
We
consent to the incorporation by reference in the registration statement (No.
333-152472) on Form S-8, registration statements (Nos. 333-61950, 333-96739,
333-103958, 333-133218, 333-142323, 333-144748 and 333-158630) on Form S-3
and registration statements (Nos. 333-114098 and 333-109114) on Form S-2 of
Antares Pharma, Inc. of our report dated March 23, 2010, with respect to the
consolidated balance sheets of Antares Pharma, Inc. as of December 31, 2009
and 2008, and the related consolidated statements of operations, stockholders’
equity and comprehensive loss, and cash flows for each of the years in the
three-year period ended December 31, 2009, which report appears in the December
31, 2009 annual report on Form 10-K of Antares Pharma, Inc (the
Company).
As
disclosed in notes 2 and 12 to the consolidated financial statements, the
Company adopted Financial Accounting Standards Board Accounting Standards Update
2009-13, Revenue Arrangements
with Multiple Deliverables, in the third quarter of 2009 with
retrospective application to January 1, 2009.
/s/ KPMG
LLP
Minneapolis,
Minnesota
March 23,
2010